Having established the anti-inflammatory efficacy of febuxostat in conditionally null Prg4 mice is a novel finding that may be a translatable finding for patients with CACP [11]. The gene discussed is PRG4; the disease is camptodactyly-arthropathy-coxa vara-pericarditis syndrome.